Skip to main content
Premium Trial:

Request an Annual Quote

Ambry to Use New RainDance Enrichment System for Targeted Sequencing

Premium

Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.

RainDance plans to officially launch the system, dubbed ThunderStorm, at the American Society of Human Genetics meeting next month.

ThunderStorm is an automated system that enables enrichment of up to 96 samples per day for targeted, high-throughput sequencing. The new system uses RainDance's microdroplet-based technology to process individual single molecule PCR reactions.

As reported by In Sequence's sister publication PCR Insider, RainDance's CEO Roopom Bannerjee said that the ThunderStorm will be able to complete a targeted resequencing protocol in about 15 minutes with no hands-on time, and will enable the company to offer sequence enrichment at between $100 and $150 per sample.

Additionally, RainDance said that the system can support a range of targeted sequencing applications including candidate gene lists, regions of association, signaling pathways, and deep sequencing of heterogeneous tumor samples.

Ambry's vice president of business development, Ardy Arianpour, said in a statement that the company plans to roll out a "portfolio of services based on this technology platform to our customers."

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.